NewLimit moves its first candidate liver reprogramming medicine into large-scale manufacturing

NewLimit/Hepatocyte epigenetic reprogramming

NewLimit moved its first candidate medicine, a payload that restores youthful function in old liver cells, into large-scale manufacturing. The company identified four candidate biomarkers to track therapeutic effects in human trials.

• First candidate advanced to large-scale manufacturing with production progress from 0 to 20% on initial batch.
• Four pharmacodynamic biomarkers identified to measure therapeutic effects in human studies.
• Timeline targets human trials within several years; manufacturing scale-up critical for clinical development.